Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 4

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  response
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Thank God it’s just COVID!

100%
Milliken A. D.
European Journal of Translational and Clinical Medicine
|
2020
|
vol. 3
|
issue 2
7-10
EN
We have been lucky with the COVID-19 pandemic: it got the attention of the first world, yet (unlike other pandemics) has not threatened the very existence of humankind. COVID-19 has given us a chance to see how well we were prepared for something that was predictable.
2
Publication available in full text mode
Content available

A Perceptionist’s View on Psychoacoustics

86%
Blauert J.
|
3
Publication available in full text mode
Content available

Fuzzy modeling and parametric analysis of non-traditional machining processes

81%
Chakraborty S., Das P. P., Chakraborty S., Das P. P.
|
|
vol. 10
|
issue 3
4
Publication available in full text mode
Content available

Leczenie choroby Alzheimera: czy istnieją możliwości przewidywania klinicznej odpowiedzi na inhibitory cholinesterazy?

72%
Flirski M., Kłoszewska I., Sobów T.
Aktualności Neurologiczne
|
2006
|
vol. 6
|
issue 2
95-107
EN
Acetylcholinesterase inhibitors are the mainstay of treatment of Alzheimer’s disease. However, in the majority of studies the proportion of patients demonstrating a significant clinical improvement under treatment does not exceed 40%. A routine method of identifying responders in clinical practice is the assessment of change in their cognitive functions during treatment. This review presents the available data on predictors of response to acetylcholinesterase inhibitor therapy in Alzheimer’s disease – factors allowing the prognosis of a patient’s reaction to treatment (in terms of target symptoms and tolerance) at its very beginning or even before therapy has been initiated. A variety of predictors will be discussed: genetic factors (apolipoprotein E, butyrylcholinesterase, choline acetyltransferase), demographic factors (age, gender), clinical factors (severity and rate of progression of dementia, comorbid neuropsychiatric symptoms, vascular risk factors, response to the test dose of the drug, results of neuropsychological testing, orthostatic hypotension), and work-up results (SPECT, MRI, EEG). The ability to predict patient’s response to treatment would allow a precise choice of szczególdrug for a given patient, taking into account its clinical efficacy in different subpopulations and potency for the generation of side effects, could also help cut down the global costs of prescribing those medications, and stimulate research on the biological mechanisms of Alzheimer’s disease. Altogether, the current level of knowledge on predictors of response to acetylcholinesterase inhibitors, with good tolerance and benign side-effect profile of this class of drugs, and lack of alternative, more effective methods of treatment of Alzheimer’s disease cannot entitle the physician to give up on the introduction of treatment in any single patient.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.